What's new? Log in Free sign up

Cosmos Health (COSM)

Company Profile

Company profile

Ticker

COSM

Exchange

Website

www.cosmosholdingsinc.com

CEO

Mr. Grigorios Siokas

Incorporated

Location

Fiscal year end

Industry (SIC)

Wholesale - Drugs, Proprietaries & Druggists' Sundries

McKesson • Cardinal Health • Cencora • Herbalife Nutrition • Nu Skin Enterprises • BIMI International Medical • Merion • Artemis Strategic Investment • HWH International • Can B ...

Former names

Cosmos Holdings Inc., PRIME ESTATES & DEVELOPMENTS INC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Cosmofarm Ltd. • SkyPharm, S.A. • Decahedron Ltd. • ZipDoctor Inc. • Cana Laboratories Holding (Cyprus) Limited ...

IRS number

270611758

COSM stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Entry into a Material Definitive Agreement

IPO registration (amended)

14 Jan 25

IPO registration (amended)

10 Jan 25

IPO registration (amended)

6 Jan 25

IPO registration

18 Dec 24

Prospectus supplement

Notice of effectiveness

IPO registration (amended)

10 Dec 24

IPO registration (amended)

27 Nov 24

Submission of Matters to a Vote of Security Holders

Latest ownership filings

View all

Grigorios Siokas

Grigorios Siokas

Grigorios Siokas

Grigorios Siokas

Grigorios Siokas

Grigorios Siokas

Georgios Terzis

Grigorios Siokas

ARMISTICE CAPITAL, LLC

Grigorios Siokas

Financial summary

Financial statements Chart COSM financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	3.31 mm	3.31 mm	3.31 mm	3.31 mm	3.31 mm	3.31 mm
Cash burn (monthly)	(no burn)	(no burn)	746.62 k	1.70 mm	(no burn)	244.29 k
Cash used (since last report)	n/a	n/a	2.97 mm	6.77 mm	n/a	970.74 k
Cash remaining	n/a	n/a	348.00 k	-3.46 mm	n/a	2.34 mm
Runway (months of cash)	n/a	n/a	0.5	-2.0	n/a	9.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

COSM institutional ownership history Ownership history

0.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	2	14	-85.7%
Opened positions	0	13	EXIT
Closed positions	12	0	NEW
Increased positions	1	0	NEW
Reduced positions	1	0	NEW

13F shares	Current	Prev Q	Change
Total value	129.73 mm	418.80 mm	-69.0%
Total shares	126.68 k	605.05 k	-79.1%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Geode Capital Management	124.70 k	$129.72 mm	+20.7%
Simplex Trading	1.99 k	$2.00 k	-40.6%
Proequities	0.00	$0.00
Compagnie Lombard Odier SCmA	0.00	$0.00	EXIT

Largest transactions	Shares	Bought/sold	Change
BLK BlackRock	0.00	-291.07 k	EXIT
Vanguard	0.00	-134.83 k	EXIT
STT State Street	0.00	-24.74 k	EXIT
Geode Capital Management	124.70 k	+21.38 k	+20.7%
NTRS Northern Trust	0.00	-20.55 k	EXIT
HRT Financial	0.00	-11.77 k	EXIT
Group One Trading	0.00	-9.88 k	EXIT
Tower Research Capital	0.00	-4.81 k	EXIT
Simplex Trading	1.99 k	-1.36 k	-40.6%
Compagnie Lombard Odier SCmA	0.00	-320.00	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

COSM insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
22 Jan 25	Siokas Grigorios	Common Stock, par value $.001	Buy	Acquire P	No	No	0.7712	38,900	30.00 k	4,203,689
17 Jan 25	Siokas Grigorios	Common Stock, par value $.001	Buy	Acquire P	No	No	0.8574	29,158	25.00 k	4,164,789
16 Jan 25	Siokas Grigorios	Common Stock, par value $.001	Buy	Acquire P	No	No	0.835	47,904	40.00 k	4,135,631
15 Jan 25	Siokas Grigorios	Common Stock, par value $.001	Buy	Acquire P	No	No	0.8	62,500	50.00 k	4,087,727
14 Jan 25	Siokas Grigorios	Common Stock, par value $.001	Buy	Acquire P	No	No	0.6877	87,247	60.00 k	4,025,227

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Cosmos Health Secures Buy-Out Rights, Exclusive Licensing For Two Patented Anticancer Drugs, Addresses Prostate, Ovarian, Colorectal Cancers; Fair Value Set At $24.61M USD; Option To Buy Out For $7.81M USD; Clinical Phase I Trials To Commence

Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical

Cosmos Health CEO Greg Siokas Bought 647,809 Shares Valued At $425,000 Between December 20, 2024, And January 17, 2025; Now Beneficially Owns 4,164,789 Common Shares In Cosmos Health

Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical

Cosmos Health Q3 EPS $(0.45) Misses $(0.11) Estimate, Sales $12.41M Miss $14.50M Estimate

Cosmos Health (NASDAQ:COSM) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.11) by 309.09 percent. This is a 66.67 percent decrease over losses of $(0.27) per share from

Cosmos Health Sees FY27 Revenue To Increase By 163%, From $59.35M In 2024 To $155.80M In 2027; Gross Profit To Grow By 653%, From $6.25M In 2024 To $47.06M In 2027; Gross Profit Margin To Expand By 1,970 Basis Points, From 10.50% In 2024 To 30.20% In 2027; Net Income To Increase By 402%, Reaching $20.44M In 2027, Compared To A Loss Of $6.76M In 2024; Adjusted EBITDA To Grow To $29.40M In 2027, From A Loss Of $1.21M In 2024.

Press releases

From Benzinga Pro

Cosmos Health Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow

CHICAGO, IL / ACCESS Newswire / January 28, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative

Cosmos Health Submits Patent Application for Allergic Inflammation Therapy by Leveraging AI Drug Repurposing; Allergy Treatment Market Valued at $23.5 Billion

CHICAGO, IL / ACCESS Newswire / January 27, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in

Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.